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ABSTRACT 
IN THE SURGICAL PATIENT REQUIRING NEUROMUSCULAR BLOCKADE, IS 
THERE AN INCREASED INCIDENCE OF POSTOPERATIVE ADVERSE 
RESPIRATORY EVENTS WITH ROCURONIUM OR VECURONIUM? 
by Martha Claudine Boos 
December 2015 
 It is estimated that up to 45% of surgical patients will have postoperative residual 
neuromuscular blockade (NMB) upon arrival to the postanesthesia care unit (PACU), and 
incomplete recovery can impair upper airway function and contribute to adverse 
respiratory events (Nagelhout & Plaus, 2014).  This retrospective cohort study examined 
whether there was an increased incidence of postoperative adverse respiratory events 
with the neuromuscular blocking agents Rocuronium or Vecuronium.  Inclusion criteria 
included any surgical patient aged 18-65, receiving NMB agents Rocuronium or 
Vecuronium during the procedure.  Exclusion criteria included any surgical patient aged 
18-65 with ASA classification > 4, any emergent cases, any patient with documented 
neuromuscular disorder or history of prolonged intubation, and patients arriving intubated 
preoperatively.  A Pearson Chi-Square test statistic was used to evaluate whether the 
patients receiving Rocuronium experienced a greater increase in post-operative adverse 
respiratory events compared with the patients whom received Vecuronium.    
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CHAPTER I 
 
INTRODUCTION 
Statement of the Problem 
 General anesthesia is the act of rendering a patient unconscious and 
unresponsive to painful stimuli, and in some general anesthesia cases, the usage of 
a NMB is also required.  Their action is to block acetylcholine from activating 
nicotinic receptors on skeletal muscles, and acetylcholine is the neurotransmitter 
responsible for muscle contraction (Guyton & Hall, 2011).  Therefore, NMB 
agents produce muscle relaxation that facilitate tracheal intubation and optimize 
the surgical field.  However, with the use of these agents, residual neuromuscular 
blockade can occur which can impair upper airway function contributing to 
adverse respiratory events in the postanesthesia care unit (PACU).  Given that 
postoperative NMB is a potentially preventable incident, it is important to find 
ways to prevent this patient safety problem from occurring.   
Clinical Question 
 In the surgical patient requiring neuromuscular blockage, is there an 
increased incidence of adverse respiratory events with the usage of the 
intermediate acting agent Rocuronium or Vecuronium?  Confounding variables 
such as length of procedure, age, gender, comorbidities, dosages of 
neuromuscular blocking agent administered, train-of-four (TOF) testing, 
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inhalation agent utilized, and if a reversal agent was administered, were 
examined.   
Problem Statement 
 Each year approximately 74 million individuals will undergo surgery, and 
of these, approximately 60% will receive general anesthesia and some form of a 
neuromuscular blockade agent (Advisory Board Company, 2014; CDC, 2014).  It 
is estimated that up to 45% of patients will have postoperative residual 
neuromuscular blockade upon arrival to the postanesthesia care unit (Nagelhout & 
Plaus, 2014).  This incomplete recovery of neuromuscular function can impair 
upper airway function and contribute to adverse respiratory events.  In the United 
States, up to 3% of these patients with residual neuromuscular blockade will 
experience clinically evident events such as serious respiratory complications, and 
these events are associated with increase in morbidity and mortality (Nagelhout, 
2013).  Furthermore, according to the Agency for Healthcare Research and 
Quality (AHRQ), these adverse events and other adverse medical events cost the 
United States in excess of 19.5 billion dollars annually (AHRQ, 2011).   
Purpose of the Project 
 The purpose of this capstone project was to determine if surgical patients 
receiving Rocuronium or Vecuronium are at a greater risk of experiencing an 
adverse respiratory event.  Variables, such as length of procedure, age, gender, 
comorbidities, dosages of neuromuscular blocking agent administered, train-of-
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four (TOF) testing, and if a reversal agent was administered, were all addressed.  
Results were disseminated, and a white paper change proposal was shared with 
the identified key stakeholders in an effort to reduce future incidence of adverse 
respiratory events associated with residual neuromuscular blockade in the 
postoperative patient.   
Conceptual and Theoretical Framework 
 Integrating nursing theory into practice provides the foundation for which 
nurses pursue understanding of patients and their health concerns.  Therefore, the 
purpose of nursing theories is to guide the care and improve patient outcomes.  In 
exploring the many nursing theories that could apply to this capstone project, the 
Neuman’s systems model theory was identified.  The Neuman’s systems theory is 
a systems-based guide that focuses on person, environment, health, and nursing 
(Whetsell, Gonzalez, & Moreno-Fergusson, 2011).  The theory involves patient 
processes and outcomes, and is based on the client’s perception, reaction, and 
resolution to stress.  The three main concepts of Neuman’s systems theory include 
stress, homeostasis, and patient perception.  The theory is based on wholism, with 
a focus on stress and systematic feedback loops, and takes into account all the 
variables that can affect a patient’s response to stress (Neuman, 1995).  
Furthermore, “Neuman considered all variables affecting a client’s response to 
environmental stressors and explains that knowing something about one part of a 
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system enables us to know something about another part” (Whetsell et al., 2011, 
p. 431).   
 The Neuman’s model focused on three types of prevention that help 
promote wellness.  The three types of prevention include primary, secondary, and 
tertiary. According to Zaccagnini and White (2014), primary prevention involves 
identifying stressors before the patient encounters the stressor; secondary 
prevention involves assisting the patient to overcome the stressor once it has 
occurred; and tertiary prevention involves focusing on maintaining wellness after 
the patient has encountered a stressor.  Lastly, the Neuman’s systems theory 
envelops a total person approach by evaluating the environment and 
understanding how the environment affects the patient.    
 In the field of anesthesia, the Neuman’s systems theory can be applied in 
several aspects of nursing care. The bulk of interventions carried out by the 
anesthesia providers are aimed at decreasing physical and emotional stress. As 
stated before, the Neuman’s theory focuses on stress and the variables that affect 
the client’s response to that stress.  Therefore, in preforming a pre-anesthetic 
evaluation, factors that can influence the perceptions of the client can be 
identified.  These factors, or variables, can be taken into account while developing 
an anesthetic plan for that patient.  Striving to maintain the normal line of defense 
by blocking those identified stressors can help the anesthesia provider maintain a 
homeostatic environment for the patient.  From the initial preoperative evaluation, 
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through the administration of agents such as anxiolytics, vagolytics, and 
anesthetics, to the postoperative examination, these actions can be performed in 
an attempt to maintain homeostasis (Martin, 1996).  All of these actions or 
interventions are aspects of applying Neuman’s systems theory into the advanced 
nursing practice of anesthesia.   
The area of interest for this study involved comparing the incidence of 
postoperative adverse respiratory events in patients receiving Rocuronium versus 
Vecuronium for neuromuscular blockage during surgery.  Adverse respiratory 
events can include hypoxia, delayed extubation, or a patient requiring reintubation 
after a surgical procedure.  For this capstone, a retrospective analysis was 
performed. Variables such as gender, age, American Society of Anesthesiologists 
(ASA) classification, type of surgery, length of surgery, number of doses of each 
medication (total dose administered), reversal (full, partial, or none), train-of-four 
documentation, temperature, body mass index (BMI), comorbidities, reintubation 
rate percentage for each NMB agent, length in PACU, inhalation agent used, and 
disposition (discharged home, transferred to ICU, expired) were identified and 
analyzed to consider their affects upon systems.  Furthermore, this capstone 
utilized the Neuman’s theory by evaluating the anesthetic process and outcomes 
of the patients included within the analysis of data.   
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Needs Assessment 
 Thousands of surgeries are performed every day in the U.S., with the 
majority of these being done as ambulatory procedures.  Advances in medical 
technology and improvements in anesthesia now allow patients to regain 
consciousness quicker and return home faster without complications. While most 
patients will not experience an adverse event, a few will experience 
complications.  
 Several preexisting factors are known to increase the risk of postoperative 
pulmonary complications associated with residual neuromuscular blockade.  
These factors include renal impairment, liver impairment, preexisting lung disease 
such as chronic obstructive pulmonary disease, asthma, or emphysema, poor 
health, obesity, and smoking (Yoder & Sharma, 2011).  Fluid and electrolyte 
imbalances, hypothermia, drug interactions, neurological and muscular diseases, 
and genetics may affect the patients’ ability to overcome the effects of residual 
muscular paralysis (Wilson, Collins, & Rowan, 2012).  Other factors include 
advanced age and male gender.  Abdominal or orthopedic surgeries and the length 
of the surgery have been shown to increase the risk of residual paralysis.  Finally, 
the anesthetic variables that potentiate adverse effects include the usage of 
neuromuscular blockage agents, opioids, and general anesthesia (Murphy et al., 
2008).  
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The patient with the greatest risk of an adverse respiratory event 
associated with residual neuromuscular blockade would include those with a 
history of Chronic Obstructive Pulmonary Disease (COPD) and smoking.  COPD 
is the third leading cause of death in the United States, and 90% of the diagnoses 
cases are individuals over the age of forty-five (American Lung Association, 
2011).  Therefore, this disease can pose a major risk for those undergoing any 
procedure, especially one requiring general anesthesia.  
 Obesity and a history of apnea are also syndemically associated.  
Increased fat deposition in the pharynx can cause compression and obstruction to 
the airway tract.  Therefore, if residual paralysis is allowed to occur, this can 
potentially increase the risk of the patient requiring reintubation due to airway 
obstruction.  Finally, renal and liver impairment can prolong the effects of 
neuromuscular blockade.  The kidneys and/or the liver metabolize all anesthetic, 
analgesic, opioid, and muscle relaxant drugs.  Therefore, if a patient has liver or 
renal disease, this can and will prolong the effects of all medications (Morgan, 
Mikhail, & Murray, 2007).  In reviewing the factors that increase the risk of 
residual neuromuscular blockade, all are noted components associated with the 
majority of patients whom receive care at the facility of choice.  
 Determining which nondepolarizing agent has a higher incidence of 
residual neuromuscular blockade resulting in adverse respiratory events will be a 
great strength and benefit to the identified key stakeholders at the hospital.  
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However, one weakness of the project could involve anesthesia providers feeling 
threatened by the review of patient data in regards to the anesthesia technique 
utilized and outcome results.  The opportunity of completing the outcome analysis 
of the capstone will reveal and answer the question if Rocuronium is associated 
with an increase in adverse respiratory events in surgical patients requiring 
neuromuscular blockade during surgery. Thus results will determine possible 
change in practice.  A threat to the project may involve the data revealing that no 
significant difference in outcomes with the usage of Rocuronium over 
Vecuronium, but that the incidence may be related to other variables not within 
the provider’s control.   
Significance and Implications 
 The significance of this capstone was to determine if there is an increased 
incidence of adverse respiratory events with Rocuronium versus Vecuronium.  If 
there is an increased incidence of adverse respiratory events with Rocuronium 
over Vecuronium, then those results will be disseminated to the anesthesia 
department in a white paper proposal with the aim to improve future surgical 
outcomes.  In addition, each variable was evaluated in an effort to determine if 
practice changes should occur to improve the possibility of an adverse event.  As 
stated before, according to the Agency for Healthcare Research & Quality, these 
adverse events and other adverse medical events cost the United States in excess 
of 19.5 billion dollars annually (AHRQ, 2011).  Furthermore, according to Zhang 
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et al. (2009), these adverse events can extend OR time contributing to high cost 
utilization.   
 If this capstone demonstrates to provide statistically significant 
information, a pilot study could be performed.  The recommendations made with 
the white paper proposal could be tested to verify feasibility and accuracy of the 
proposed changes.  According to Gearing, Mian, Barber, and Ickowicz (2006), a 
pilot study is basically a small version of a proposed research plan that can offer 
researchers valuable information.  If that data suggests that Rocuronium has a 
greater incidence of adverse respiratory events, this information could guide the 
anesthesia provider in the future in an effort to improve patient outcomes.   
Review of Literature 
Each year approximately 70 million individuals will undergo surgery, and 
of these, approximately 60% will receive general anesthesia and some form of a 
neuromuscular blockade agent (Advisory Board Company, 2014; CDC, 2014).  In 
fact, it is estimated that approximately 45% of postoperative patients will have 
residual neuromuscular blockade upon arrival to the recovery room (Nagelhout & 
Plaus, 2014).  However, approximately 90% of United States anesthesia providers 
and 80% of European anesthesia providers say they have never encountered this 
issue (Murphy, 2012).   It is believed this discrepancy is due to the providers not 
recognizing the signs and symptoms of residual paralysis, and choosing to relate 
the adverse events to obesity or some other probable comorbidity issue.  In 
10 
 
   
addition, 6 out of every 10 surgeries will be performed as a same-day operative 
procedure, and one may think there are minimal risks associated with such 
procedures. However, approximately 100,000 individuals will experience adverse 
respiratory events related to residual neuromuscular blockade (Marcus, 2012).  
General anesthesia is the act of producing unconsciousness and 
unresponsiveness to all painful stimuli, and in some general anesthesia cases, the 
usage of a muscle relaxant or neuromuscular blockade agent is also required 
(Lehne, 2004).  Nondepolarizing neuromuscular blocking agents are used to 
prevent undesired patient movement during some surgical procedures.  Their 
action is to block acetylcholine, which is responsible for muscle contraction, from 
activating nicotinic receptors on skeletal muscles (Guyton & Hall, 2011).  NMB 
produces muscle relaxation to assist the surgeon in procedures that require 
complete relaxation such as in abdominal cases.  However, with the use of these 
agents, risks are involved if not monitored closely by the anesthesia provider.  
Lastly, as stated before, several adverse effects are associated with the use of 
neuromuscular blockade agents such as respiratory depression, aspiration, airway 
obstruction, and muscle weakness (Wilson et al., 2012).   
Residual neuromuscular blockade is not a new phenomenon.  In fact, over 
60 years ago, Dr. Henry Knowles Beecher and Dr. Donald Todd published a study 
in the Annals of Surgery regarding this issue.  Their study involved ten hospitals 
and 599,548 anesthetic procedures administered between 1948 and 1952 (Beecher 
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& Todd, 1954).  According to their study, patients administered a neuromuscular 
blockade agent had a six-fold increase in mortality than patients not administered 
a neuromuscular blockade agent (Beecher & Todd, 1954).  Most of the causes of 
death were related to patient disease process, surgical management, anesthetic 
management, and adverse respiratory events.  In the 1970s, studies were 
performed by Viby-Mogensen, and they concluded approximately 42% of patients 
had residual paralysis upon arrival to the recovery unit (Murphy, 2012).  In the 
1980s, studies concluded 21% to 36% had residual from the neuromuscular 
blockade agent, and in the mid 2000s, several compiled studies revealed residual 
in as high as 65% of the patients (Murphy, 2012).  Many studies over the last 20 
years have involved healthy subjects whom volunteered to undergo procedures 
with neuromuscular blockage agents.  The end results concluded that there were 
two main adverse events associated with residual neuromuscular blockade.  Those 
adverse events included airway obstruction and extreme muscle weakness.  With 
this investigation, it also concluded that 33% reported upper airway obstruction, 
and over half complained of the impaired ability to swallow (Murphy, 2012).  
However, the relevant question is whether the problem exists in anesthesia today? 
 Currently, as many as 100,000 patients experience some form of an 
adverse respiratory event after surgery linked to residual neuromuscular blockade 
agents.  This accounts annually for approximately 0.8% of the patients, with 0.1% 
of the patients requiring reintubation due to the residual respiratory paralysis 
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(Marcus, 2012).  Recently, in a study conducted by Murphy and colleagues, data 
were collected over a one-year period on 7,459 patients whom received general 
anesthesia.  Of those, approximately 0.8% demonstrated residual neuromuscular 
blockade and suffered a critical respiratory event (Murphy et al., 2008).  The 
study suggested that incomplete recovery from neuromuscular blockade is an 
important contributing factor in postoperative adverse respiratory events.   
Potential Legal Implications of an Adverse Event 
According to the Agency for Healthcare Research and Quality (AHRQ), 
these adverse events and other adverse medical events cost the United States in 
excess of 19.5 billion dollars a year (AHRQ, 2011).  However, this is not just an 
U.S. issue, it occurs globally.  In fact, to help decrease the incidence, the 
Association of Anaesthetists of Great Britain and Ireland require nerve stimulators 
be available whenever a neuromuscular blockade agent is administered during 
surgery and must be available in the recovery unit (Marcus, 2012).  One study 
conducted in the Netherlands involved approximately 870,000 patients.  The 
investigation determined that poor management of neuromuscular blockade 
agents was the most significant factor for death or coma.  The study also 
concluded that usage of reversal agents reduced the mortality rates by 90%, 
compared to not using reversal agents.  Lastly, a study conducted in South Africa 
involving over 240,000 patients concluded that respiratory failure related to 
residual paralysis was the second leading cause of death attributed to anesthesia, 
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following hypovolemia which was the leading cause of death (Murphy, 2012).  As 
one can conclude, this is a global issue that requires further investigation and 
review of standards.  
A literature review conducted by MacRae (2007) involving 7,117 closed 
anesthesia claims revealed lack of vigilance is believed to be the leading cause of 
all adverse events.  In fact, despite the fact that airway management is considered 
the anesthesia provider’s area of expertise, difficultly in managing the airway is 
the leading cause of morbidity and mortality for anesthesia.  According to 
MacRae (2007), results from the closed claims studies in anesthesia revealed that 
approximately 45% of the cases were related to respiratory events, 31-32 % to 
death or brain damage, 25% to a cardiovascular event, and approximately 21% to 
nerve injury.  Anesthesia providers must be aware that the median cost of a 
malpractice suit is approximately $300,000 (Bishop, Ryan, & Cassalino, 2011).  
Therefore, it is important to identify and examine preventive measures that could 
decrease this incidence.   
Current Recommended Prevention Measures 
 There are several recommended measures all anesthesia providers can 
perform to potentially decrease the incidence of residual neuromuscular blockade.  
On December of 2012, the Anesthesia Patient Safety Foundation (APSF) 
sponsored a panel titled, “Residual Muscle Relaxant Induced Weakness in the 
Postoperative Period: Is It a Patient Safety Issue?” According to Morell (2013), 
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the panel of experts agreed that routine monitoring of neuromuscular blockade 
should be performed routinely and a train-of-four (TOF) ratio of >0.9 is an 
appropriate goal.  The panel of experts concluded that lesser TOF ratios could 
increase the potential for adverse events, both short-term and long-term (Morell, 
2013).  According to Stoelting (2014), following the APSF meeting, a survey was 
conducted using random sampling of 25% of the active members (21,482), and 
resulted with 90% of respondents agreeing that there is a need for routine 
intraoperative monitoring of neuromuscular blockade.  Furthermore, the survey 
results also overwhelmingly recommended the APSF should encourage the 
American Society of Anesthesiologists (ASA), American Association of Nurse 
Anesthetists (AANA), and American Academy of Anesthesiologist Assistant 
(AAAA) to adopt monitoring neuromuscular function as part of their standards of 
care.  
 According to Foster and Callahan (2011), “standards are rules or 
minimum requirements that describe specific responsibilities and principles of 
patient care and define the expectations against which professional performance 
can be measured” (p. 157).  Since that time, the AANA, ASA, and AAA have 
adopted such a standard or recommendation.  According to the AANA Standards 
for Nurse Anesthesia Practice (2013), “when neuromuscular blocking agents are 
administered, monitor neuromuscular response to assess depth of blockade and 
degree of recovery” (p. 2).  Therefore, to adequately monitor the depth of 
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blockade and degree of recovery, the anesthesia provider must utilize certain 
techniques such as physical assessment and the use of a peripheral nerve 
stimulator.  
 The peripheral nerve stimulator is a device that verifies the TOF 
responses.  The TOF is a series of four minimal shocks that are applied to a 
peripheral nerve such as the facial nerve.  The anesthesia provider will count the 
number of twitches elicited from the 4 shocks.  If 4 twitches are observed, this 
could indicate that approximately 0-75% of the receptors are still blocked.  Three 
twitches indicate approximately 75% are blocked.  Two twitches could mean 
approximately 80% are blocked, and no twitches would indicate 100% blockage 
(Saenz, 2011).   
 The percentage of blockage is directly related to the amount of muscle 
relaxant or paralysis (Nagelhout & Plaus, 2014).  The anesthesia provider will 
observe for a fade.  A fade is a decreasing in amplitude noted with the twitches, 
and this result is directly related to the amount of paralysis present from the 
neuromuscular agent.  Therefore, as a primary prevention, the anesthesia provider 
should utilize the TOF when monitoring the patient to determine readiness for 
extubation at the end of the procedure. However, not all anesthesia providers 
utilize the TOF monitoring device.  In fact, it is estimated only 22% of the 
practitioners in the U.S., and only 70% of the European anesthesia providers 
report using this TOF device (Donati, 2010).   
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 Another recommended prevention measure is routine pharmacologic 
reversal of a nondepolarizing neuromuscular blockade (Miller & Ward, 2010).  
After an extensive review, Miller and Ward (2010) stated their opinion as, “these 
databases and our own review of many cases of adverse outcomes has led to the 
conclusion that reversal of NMB with neostigmine should be routine.  
Conversely, there should be written documentation as to why neostigmine was 
unnecessary” (p. 2).  According to the Neostigmine package insert, Neostigmine 
inhibits the hydrolysis of acetylcholine by directly competing with acetylcholine 
for cholinergic receptor sites, has a half life of 24 – 113 minutes, should be 
administered slowly over at least one minute, and takes a minimum of 10 minutes 
to achieve a TOF of 90% reversal (Eclat Pharmaceuticals, 2014).  As 
acetylcholine levels build, a return of muscle contraction begins thereby reversing 
the effects of the NMB.  According to Nagelhout (2013), the recommended 
protocol is to have a minimum of 2 twitches from a TOF when neostigmine is 
administered.  Lastly, according to Eclat Pharmaceuticals (2014), since 
Neostigmine has a direct postsynaptic cholinergic effect, these effects can be 
managed by administration of glycopyrrolate or atropine in a separate syringe 
prior to Neostigmine administration.  
 One retrospective cohort study concluded that patients whom received a 
reversal agent were associated with a reduction of elapse operating room (OR) or 
PACU time (Zhang, et al., 2009).  The retrospective study involved reviewing 
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9670 elective surgeries performed under general anesthesia and using one or more 
neuromuscular blocking agents.  The study concluded that utilizing a reversal 
agent may lead to more efficient OR resources since the reversal agent was shown 
to reduce OR time 12 to 46 minutes in the majority of the surgical cases (Zhang et 
al., 2009).  Brull, Kopman, and Naguib (2013), reported successful antagonism is 
enhanced when the antagonist such as neostigmine is administered 15 to 20 
minutes before tracheal extubation and when there is a TOF of 4 twitches.   
However, routine reversal is not a common practice.  In fact, only 34% of 
clinicians in the United States and 18% of anesthesia providers from Europe 
report routine usage (Nagelhout, 2013).  In a survey conducted involving 108 
clinical anesthesiologists, the decision to reverse a neuromuscular blocking agent 
was based on the pharmacological knowledge of the medication and on personal 
judgment of patient breathing (Videira & Vieira, 2011).  According to Videira and 
Vieira (2011), “clinicians judge themselves as better skilled at avoiding residual 
block than they do their colleagues, making them overconfident in their capacity 
to estimate the duration of action of intermediate-acting NMBD” (p. 1192).  
Comparison of Rocuronium and Vecuronium 
 Rocuronium and Vecuronium are two nondepolarizing relaxants with 
similar efficacy.   Rocuronium is usually the drug of choice on induction and is 
widely used when succinylcholine, a depolarizing relaxant, is contraindicated.  
Rocuronium has a faster onset or 45 to 90 seconds, duration of 30 to 60 minutes, 
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undergoes both hepatic and renal elimination, and has an elimination half-life of 
60 to 120 minutes (Nagelhout & Plaus, 2014).  In comparison, Vecuronium is also 
an intermediate acting nondepolarizing agent with an onset of 3.1 minutes, 
duration of 30 to 45 minutes, undergoes hepatic and renal elimination, and has an 
elimination half-life of 51 to 91 minutes (Nagelhout & Plaus, 2014).  In addition, 
reversal of the effects of these nondepolarizing relaxants requires time or the 
usage of an anticholinesterase agent.   
 Several studies have evaluated the incidence and duration of postoperative 
residual neuromuscular blockade between Vecuronium, Rocuronium, and other 
non-depolarizing muscle relaxants.  One such study conducted by Khan, Divatia, 
and Sareen (2006), concluded that residual neuromuscular blockade was 
significantly higher with Rocuronium at 37% compared to 17% with Vecuronium.  
In another study involving 60 patients, 20 received Rocuronium, 20 received 
Vecuronium, and the other 20 received Cisatracurium.  The results concluded that 
intubation times were shorter in those receiving Rocuronium, recovery time was 
faster with Cisatracurium, and TOF was significantly longer with Rocuronium 
(Sagir et al., 2013). Several studies revealed patients could experience residual 
paralysis for several hours after neuromuscular blockade administration.   
 One such study involved 526 patients whom received a single intubating 
dose of Rocuronium, Vecuronium, or Atricurium and did not receive a reversal 
agent.  The TOF ratio was measured upon admission into the PACU, and the 
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study concluded that residual paralysis is common even more than 2 hours after 
administration of an intubating dose of an intermediate acting muscle relaxant 
(Debaenne, Plaud, Dilly, & Donati, 2003).  In a case report involving an 84 year-
old female undergoing elective hysterectomy and receiving a one-time intubating 
dose of Rocuronium, the study revealed that it might take more than 3.5 hours 
before it is possible to antagonize a block (Claudius, Karacan, & Viby-Mogensen, 
2007).  Therefore, one may conclude from these studies, when deciding which 
intermediate-acting non-depolarizing muscle relaxant to utilize, Vecuronium may 
be the more reliable choice.  However, further studies may be beneficial.    
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CHAPTER II 
METHODOLOGY 
 The purpose of this capstone project was to determine if surgical patients 
receiving Rocuronium or Vecuronium are at a greater risk of experiencing an 
adverse respiratory event.  The methodology of this capstone will follow this 
order: 1) Setting, 2) Target Outcomes, 3) Barriers, 4) Populations, 5) Sampling, 6) 
Research Strategies, 7) Methods, and 8) Measurement Methods. 
Setting 
 The capstone setting for this retrospective analysis took place at a level II 
regional trauma center located in Hattiesburg, Mississippi.  It is a 512-bed facility 
offering services to the surrounding 19 counties, performing over 7000 inpatient 
and 9900 outpatient procedures each year (Forrest General Hospital, 2014).  In 
2013, the hospital successfully installed the Electronic Patient Integrated Care 
(EPIC) system. Therefore, this hospital provided an excellent setting to perform 
the retrospective analysis.   
Target Outcome 
 The desired goal for this capstone was to determine if surgical patients 
requiring neuromuscular blocking agents are at a greater risk of experiencing an 
adverse respiratory event with the intermediate acting agents Rocuronium or 
Vecuronium.  The desired outcome of the project was to develop a practice 
change policy based upon the results in an effort to improve patient safety. The 
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results of the retrospective review were shared with the identified key 
stakeholders in an effort to further reduce future incidence of adverse respiratory 
events associated with residual neuromuscular blockade in the postoperative 
patient.   
Barriers 
 Some barriers this project encountered included time constraints, a limited 
number of providers whom utilize Vecuronium as the neuromuscular blocking 
agent of choice upon induction of anesthesia, the inability to discover an existing 
data abstraction tool specific to this capstone project, and the limited number of 
cases in which anesthesia providers re-dose paralytics. 
Populations 
 A total of 50 subjects, 25 in each group, whom received either 
Rocuronium or Vecuronium, were chosen for the retrospective analysis.  The 
inclusion population included any surgical patient ages 18-65 whom either 
received an intubating dose or where re-dosed with the NMB agents Rocuronium 
or Vecuronium during the procedure. Exclusion criteria included any surgical 
patient ages 18-65 with ASA classification > 4, any emergent cases, any patient 
whom only received a defaciculating dose of Rocuronium or Vecuronium, any 
patient with documented neuromuscular disorder or history of prolonged 
intubation, and patients arriving intubated preoperatively.  
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Sampling 
 Since every retrospective chart review requires a statistical power analysis, 
one was completed to determine the appropriate sample size.  In addition, 
convenience sampling, which is the most common method, was utilized.  With 
convenience sampling, the subjects included in the study are used because they 
“happened to be in the right place at the right time” (Grove, Burns, & Gray, 2013, 
p. 363).  Of course, with this sampling, the researcher continued to enter subjects 
into the study until the desired sample size was obtained.  
 To prevent bias during sampling and collection of data, the investigator 
employed a specific procedure of review.  First, each time the investigator audited 
charts, a different month of surgical cases were reviewed.  Upon entering the 
health record for the first case, the gender was obtained and then the age.  If the 
patient was under the age of 18 or over the age of 65, the audit ceased.  Next, the 
ASA was viewed.  If the ASA was greater than 4 or classified as an emergent 
case, the audit ceased.  If criteria were found appropriate, comorbidities, the 
inhalation agent used, temperature, and BMI were recorded.  Then the paralytic 
agent was reviewed.  If the patient was not intubated with the paralytic 
Rocuronium or Vecuronium, or was not re-dosed with one of these agents, the 
audit of this chart ceased.  If criteria were found appropriate to this point, the total 
doses of Rocuronium or Vecuronium, reversal, TOF, and all other variables found 
on the data abstraction tool were recorded.   Next, the investigator reviewed the 
23 
 
   
first vital signs recorded in the PACU area after surgery.  If an adverse respiratory 
event was noted, the data received a yes in the adverse event category.  If not, a 
no was recorded.  Data were collected until minimum of 25 charts were audited of 
patients whom had received Rocuronium and 25 whom had received Vecuronium.  
Lastly, to prevent bias, the investigator only included the data of the first 25 
whom received Rocuronium regardless of the outcomes, and the first 25 of those 
whom received Vecuronium, regardless of if an adverse event occurred.   
Research Strategies 
 To explore the capstone question in the surgical patient requiring 
neuromuscular blockade, is there an increased incidence of postoperative adverse 
respiratory events with Rocuronium or Vecuronium a retrospective cohort study 
was completed.  A retrospective cohort study is a study in which the researcher 
identifies a group of people (Rocuronium versus Vecuronium recipients) who 
have experienced a particular event (adverse respiratory event).  Therefore, a 
retrospective analysis of de-identified electronic health record data was 
performed.  Inclusion criteria included all surgical patients whom received NMB 
of Rocuronium or Vecuronium during the procedure. Exclusion criteria included 
any surgical patient with ASA classification > 4, any emergent cases, any patient 
with documented neuromuscular disorder or history or prolonged intubation, and 
patients arriving to OR previously intubated.   
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 The study involved the collection of existing data from the electronic 
medical record, and not any experimental procedures.  Confidentiality of records 
was maintained throughout the collection of data from the electronic health 
record.  The investigator in such a manner recorded all information that subjects 
cannot be identified, directly or indirectly.  
 After data was analyzed, results were shared with key identified 
stakeholders, and a white paper proposal was formulated.  According to the 
AANA (2014), a white paper is “complete descriptions of a particular concept, 
position or solution to a problem, from overview to detailed facts, created to 
promote professionalism and advocacy. Intended to guide decision-makers on 
policy development” (p. 2).   Therefore, as stated before, a white paper proposal 
was formulated after all data was collected and reported in a manner in which the 
subject were not and could not be identified.   
Methods 
 After obtaining approval from the institutional review board (IRB) at the 
university and the clinical site, the retrospective analysis began.  A retrospective 
analysis of de-identified electronic health record data was performed using a 
medical record abstraction form.  According to Banks (1998), a well-designed 
data abstraction tool is designed to promote accuracy of data transcription, limit 
the likelihood of missing data, and is designed to promote accurate data entry into 
the computerized database for analysis.   This investigator developed a data 
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abstraction tool that included the variables of gender, age, ASA classification, 
type of surgery, length of surgery, number of doses of each paralytic (total dose 
administered), reversal (full, partial, or none), inhalation agent used during 
procedure, TOF documentation, TOF documentation when reversed, temperature, 
BMI, comorbidities, time of last dose of paralytic to reversal, time of last 
dose/reversal to extubation time, narcotic used, dose of narcotic, and if adverse 
event experienced.   
 Inclusion criteria included any surgical patients aged 18-65 receiving 
NMB of Rocuronium or Vecuronium during the procedure. Exclusion criteria 
included any surgical patient with ASA classification > 4, any emergent cases, 
any patient with documented neuromuscular disorder or history or prolonged 
intubation, and patients arriving intubated preoperatively.  A Pearson’s Chi-
Square Test was used to evaluate whether the patients receiving Rocuronium 
experience a greater increase in post-operative adverse respiratory events 
compared with the patients whom received Vecuronium. 
 Confidentiality of records was maintained throughout the collection of 
data from the electronic health record, and the investigator recorded all data in 
such a manner that subjects cannot be identified directly or indirectly. After data 
was analyzed, a white paper proposal was formulated, and results were shared 
with key identified stakeholders.   
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Measurement Method 
 The measurement methodology for this capstone involved performing a 
retrospective chart review analysis from computerized healthcare information at 
the clinical site.  According to Groves and colleagues (2013), data collected from 
stored electronic healthcare information is considered secondary data, and these 
databases provide large amounts of information relevant for research.  In addition, 
according to Gearing and colleagues (2006), data should be extracted effectively 
and systematically.  To begin, a literature review was performed to identify the 
variables that could potentiate the problem of residual neuromuscular blockade.  
After all variables were identified, a data extraction instrument was created (See 
Appendix C).   
 According to Gearing et al. (2006), data collection should be organized to 
follow the flow of the health care record.   Each variable needs a simple and 
definite response section, where the information can be captured. Internal validity 
and reproducibility of any retrospective study is greatly enhanced if the data is 
standardized (Jansen et al., 2005). Lastly, according to Allison et al. (2000), paper 
or an electronic document can be the data abstraction instrument.  
 To begin, the anesthesia record was reviewed to determine the flow of 
data in regards to the variables identified.  Second, permission from the clinical 
site was obtained to perform the retrospective analysis of the health records.  It 
was determined a paper document would be created and utilized during the chart 
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reviews, and the information would be collected in such a manner that no subjects 
could be identified.  The abstractor guaranteed in writing to destroy the paper 
document after all information had been analyzed.  As stated before, each variable 
needs a simple and definite response.  The data extraction instrument was created 
with the following legend: gender coded as M for male, F for female; age coded 
with numeric number; ASA classification coded as I, II, III, or IV; comorbidities 
coded R for respiratory issue, C for cardiac, N for neurological, H for hepatic, G 
for gastrointestinal, R for renal, E for endocrine, O for other; inhalation agent 
coded as S for sevoflurane, D for desflurane, I for isoflurane; temperature coded 
with numerical number in Celsius; BMI coded with numerical number; paralytic 
used coded as R for Rocuronium, V for Vecuronium; total dose of paralytic coded 
in numerical number as dose in milligrams; reversal agent coded T for total, P for 
partial dose, N for no reversal agent used; time of last dose to reversal coded in 
numerical number in minutes; time of last dose/reversal dose to extubation coded 
in numerical number in minutes; TOF documentation coded as Y for yes, N for 
no; TOF documentation when reversed coded as numerical number; type of 
procedure coded as A for abdominal, E for extrathoracic, O for orthopedic, H for 
head; P for perineal, I for intrathoracic, N for neuroskeletal, S for spine, V for 
vascular; length of surgery coded in numerical number in minutes; narcotic coded 
F for fentanyl, M for morphine,  D for dilaudid, P for precedex; narcotic dosage 
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coded as numerical number in milligrams; and adverse event coded as Y for yes 
or N for no.   
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CHAPTER III 
ANALYSIS OF DATA 
 The purpose of this capstone project was to perform a retrospective cohort 
analysis utilizing a well-developed data abstraction tool to determine if surgical 
patients requiring NMB were at greater risk of experiencing an adverse 
respiratory event with Rocuronium or Vecuronium.  The analysis of data is 
organized as follows: 1) Statistical Analysis, 2) Presentation of Findings, and 3) 
White Paper Change Proposal. 
Statistical Analysis 
 After data was extracted into categorical variables, a Pearson’s chi-square 
test using Statistical Package for the Social Sciences (SPSS) for association was 
performed.  With the chi-square test, it is utilized to determine if a relationship 
exists between two categorical variables.  According to Daniel (2009), the chi-
square distribution is the most frequently used statistical tool for analysis of 
frequency or count data.  Furthermore, a hypothesis and null hypothesis was 
developed.  The hypothesis for the capstone was: there is an increased incidence 
of adverse respiratory events with Rocuronium versus Vecuronium?  The null 
hypothesis was: there is not a significant increase incidence of adverse respiratory 
events with Rocuronium over Vecuronium?  Lastly, the level of significance was 
computed.  According to Daniel (2009), “the level of significance  is a 
probability and, in fact, is the probability of rejecting a true null hypothesis” (p. 
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220).  As known in statistics, an alpha of 0.05 is the maximum level in scientific 
research.  Therefore, this capstone analyzed the data at the significance level of 
0.05.   
Presentation of Findings 
 The retrospective analysis was conducted at a level II regional trauma 
center located in Hattiesburg, Mississippi over a four-month period. All surgical 
patients who underwent general anesthesia and received either Rocuronium or 
Vecuronium during the procedure were reviewed.  A convenience sample of 50 
subjects, 25 whom received Rocuronium and 25 whom received Vecuronium, 
were chosen for the project.   Inclusion criteria included any surgical patient ages 
18-65 whom received the NMB agents Rocuronium or Vecuronium during the 
procedure. Exclusion criteria included any surgical patient ages 18-65 with an 
ASA classification > 4, any emergent cases, any patient with documented 
neuromuscular disorder or history of prolonged intubation, and patients arriving 
intubated preoperatively.   
 The retrospective analysis of de-identified electronic health record data 
was performed using a paper medical record abstraction form.  Demographic 
characteristics of all patients were collected, and can be reviewed on Table 1.  
Confidentiality of the information was maintained throughout the collection of 
data, and the investigator recorded all data in such a manner that subjects cannot 
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be identified directly or indirectly.  The abstractor, as guaranteed in writing to 
IRB, destroyed the paper document after all information was analyzed.   
Table 1 
Demographic Characteristics of All Patients 
 
Characteristic    Number   Percentage 
__________________________________________________________________ 
Gender 
     Male    24    48 
     Female    26    52 
 
Age (y) 
     Mean    52.5 
     Range    18 – 65 
 
Mean length surgery (min)  126 
 
Body mass index (kg/m2) 
     Mean    27.9 
     Range    19.5 – 46.6 
 
ASA category 
     I     4    8 
     II     17    34 
     III     26    52 
     IV     3    6 
 
Type of surgery 
     Abdominal    33    66 
     Orthopedic    5    10 
 
__________________________________________________________________ 
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Table 1 (continued). 
 
__________________________________________________________________ 
 
Characteristic    Number   Percentage 
 
__________________________________________________________________ 
 
     Neurosurgery   3    6 
     Extrathoracic   2    4 
     Thyroid    3    6 
     Spine    3    6 
     Intrathoracic   1    2 
 
__________________________________________________________________ 
 
Only 7 of the sample of patients experienced an adverse respiratory event.  
Two of the patients were males, 5 were females, averaged 43 years of age (range, 
27 to 65), and average BMI was 30.9 (range, 19.5 to 39 kg/m2), placing all but 
one patient into the overweight or obese categories.  Demographic characteristics 
of these patients can be viewed in Table 2. 
Table 2 
Demographic Characteristics of Those Whom Experienced Adverse Event 
_________________________________________________________________ 
Gender      ASA   Paralytic   Age   Inhalation  BMI   Surgery     Length of 
                                                         Agent                                  Surgery (minutes) 
_________________________________________________________________ 
Female     III V 57   S   36.9       A          117 
 
__________________________________________________________________ 
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Table 2 (continued). 
 
__________________________________________________________________ 
 
Gender      ASA   Paralytic   Age   Inhalation  BMI   Surgery     Length of 
                                                         Agent                                  Surgery (minutes) 
 
__________________________________________________________________ 
Female IV V 65 S 19.5    A  153 
Male  III R 24 D 25.9    O  67 
  
Female II R 27 D 35.3    A  182 
  
Female IV R 62 S 32    N  84 
  
Male  III R 60 S 28    A  112 
  
Female III R 44 S 39    T  141 
__________________________________________________________________ 
Note.  R = Rocuronium; V = Vecuronium; D = Desflurane; S = Sevoflurane; A = Abdominal; N = Neurosurgery; T =   
 
Thyroid; O = Orthopedic; BMI – Body Mass Index 
 
 A Pearson chi-square test of independence was performed to examine the 
relationship between the paralytic used and if an adverse respiratory event 
occurred.  Of the patients whom receive the NMB agent Rocuronium, 80% did 
not experience an adverse respiratory event such as SpO2 < 90%, arrived to PACU 
intubated, or had to be re-intubated in PACU, and 20% did experience an event 
(Table 3).  Of the patients whom received the NMB agent Vecuronium, 92% did 
not experience an adverse respiratory event and 8% did experience an event.  
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Although the differences in percentages appears large, the relationship, as seen in 
Table 4, between these variables were found to be insignificant, (N=50, df=1) = 
1.495, p = 0.221.   
Table 3 
Adverse Event and Paralytic Crosstabulation 
_________________________________________________________________ 
                                                                          Paralytic     
                                                                       R                 V                           Total 
_________________________________________________________________
Adverse Event     N     Count                        20                23                      43 
                                    % within paralytic     80.0%         92.0%                86.0% 
                             Y     Count                        5                 2                         7 
                                    % within paralytic     20.0%         8.0%                  14.0% 
Total                            Count                        25                25                      50 
                                     % within paralytic    100.0%       100.0%              100.0% 
_________________________________________________________________ 
Note.  R = Rocuronium; V = Vecuronium; N = No; Y = Yes. 
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Note. df = Degree of freedom; a = 2 cells (50%) have expected count less than 5; b = Computed only for a 2 x 2 table. 
 
 Although the project did not provide a statistically significant relationship 
between adverse respiratory events and the usage of Rocuronium or Vecuronium, 
some serendipitous findings were noted.  One serendipitous finding throughout 
this project was the significant relationship found between the variables of 
adverse events and the usage of NMB reversal agent (Table 5).   
 
 
 
 
 
 
 
Table 4 
Pearson’s Chi-Square test table for Adverse Event and Paralytic 
__________________________________________________________________                                    
                                        Value               df               Asymptotic Sig. (2-sided) 
__________________________________________________________________ 
 
Pearson Chi-Square          1.498a                   1                     .221 
 
Continuity Correctionb      .664                1                     .415 
 
__________________________________________________________________ 
 
36 
 
   
Table 5 
Reversal and Adverse Event Crosstabultion 
___________________________________________________________________________________________________ 
Reversal   Adverse Event   Total 
    N  Y 
__________________________________________________________________ 
None  Count  8  5   13 
  % within 18.6%  71.4%   26.0% 
Partial  Count  15  1   16 
  % within 34.9%  14.3%   32.0% 
Complete Count  20  1   21 
  % within 46.5%  14.3%   42.0% 
Totals  Count  43  7   50 
  % within 100.0% 100.0%  100.0% 
__________________________________________________________________ 
Note.  N = No; Y = yes. 
 A Pearson’s chi-square test revealed (N=50, df=1) = 8.747, p = 0.013 
(Table 6).  Of the 7 patients whom experienced an adverse respiratory event 
postoperatively, 5 did not receive a NMB reversal agent, 1 received a partial 
dosage, and 1 received a total reversal dose.  However, it was of interest that the 
patient whom received total reversal, that patient had been re-dosed 16 minutes 
prior with Vecuronium.  As literature states, Vecuronium has a half-life of 51 to 
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91 minutes and duration of 30 to 45 minutes.  Therefore, it is probable the 
reversal dose may have potentiated the NMB thus leading to the adverse 
respiratory event.  
Table 6 
Pearson Chi-Square test table for Reversal and Adverse Event 
__________________________________________________________________ 
    Value  df Asymptotic Sig. (2-sided) 
__________________________________________________________________ 
Pearson Chi-Square  8.747a  2  .013 
Likelihood Ratio  7.651  2  .022 
Number of Valid Cases 50 
__________________________________________________________________ 
Note.  df = Degree of Freedom; Sig = Significance; a = 3 cells (50%) have expected count less than 5.  The minimum 
expected count is 1.82. 
Another serendipitous finding was that 100% of the patients whom 
experienced an adverse respiratory event had not received TOF evaluation during 
nor prior to extubation. Table 7 compares the variables of measuring TOF to 
adverse events.  Although this finding had a p value of .075 and is therefore 
considered insignificant, it is hypothesized that a larger data sampling may allow 
the variable to become statistically significant (Table 8).   
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Table 7 
TOF and Adverse Event Crosstabulation 
__________________________________________________________________ 
TOF     Adverse Event  Total 
     N  Y 
__________________________________________________________________ 
TOF  N Count  29  7  36 
  % within  67.4%  100.0% 72.0% 
  Y Count  14  0  14 
  % within  32.6%  0.0%  28.0% 
_________________________________________________________________ 
Note. N = no; Y = yes. 
Table 8 
Pearson’s Chi-Square test table for TOF and Adverse Event 
__________________________________________________________________ 
    Value  df Asymptotic Sig. (2-sided) 
__________________________________________________________________ 
Pearson Chi-Square  3.165a  1  .075 
Likelihood Ratio      .025 
__________________________________________________________________ 
Note.  df  = Degree of Freedom; Sig = Significance; a = 1 cells (25.0%) have expected count less than 5.  The minimum 
expected count is 1.96.   
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White Paper Change Proposal 
 The desired goal for this capstone project was to determine if surgical 
patients requiring NMB agents were at greater risk of experiencing an adverse 
respiratory event with the intermediate acting agents Rocuronium or Vecuronium.  
The desired outcome was to develop a white paper practice change proposal based 
upon the results in an effort to improve patient safety.  According to the AANA 
(2014), a white paper is “complete descriptions of a particular concept, position or 
solution to a problem, from overview to detailed facts, created to promote 
professionalism and advocacy. Intended to guide decision-makers on policy 
development” (AANA, 2014, p. 1).  Although no statistically significant 
relationship was found between the variables of adverse events and the paralytics 
Rocuronium or Vecuronium, unanticipated findings did occur.  The serendipitous 
results regarding the variable of the usage of a reversal agent and possibly usage 
of TOF monitoring did provide positive findings for areas of improvement.  The 
results of this capstone was shared with identified key stakeholders at the hospital 
in which the retrospective analysis occurred in an effort to further reduce future 
incidence of adverse respiratory events associated with residual neuromuscular 
blockade in the postoperative patient.   
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CHAPTER IV 
SUMMARY 
 The purpose of this capstone project was to perform a retrospective cohort 
analysis utilizing a well-developed data abstraction tool to determine if surgical 
patients requiring NMB were at greater risk of experiencing an adverse 
respiratory event with Rocuronium or Vecuronium.  This chapter is organized as 
follows: 1) Summary of Findings, 2) Recommendations, and 3) Conclusions.   
Summary of Findings 
 The major finding of the project included there is no statistically 
significant relationship between increased incidences of postoperative adverse 
respiratory events with the usage of Rocuronium over Vecuronium.  However, the 
project did provide a statistically significant relationship between adverse 
relationships and patients not being fully reversed from the NMB agent.  This 
finding correlates with the recommendation that routine pharmacologic reversal 
of a nondepolarizing NMB should occur.  Furthermore, the project determined 
that TOF monitoring is only occurring 28.0% of the time even though this is 
considered an AANA Standard.  According to the AANA Standards for Nurse 
Anesthesia Practice (2013), the standard is as follows: “when neuromuscular 
blocking agents are administered, monitor neuromuscular response to assess depth 
of blockade and degree of recovery” (p. 2).  Therefore, to adequately monitor the 
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depth of blockade and degree of recovery, the anesthesia provider should utilize 
certain techniques such as physical assessment and TOF monitoring.  
Recommendations 
 Given the relatively small sample size and short duration of the 
retrospective analysis, it is recommended the proposed changes made with the 
white paper proposal be tested to verify feasibility and accuracy of the proposed 
changes.  Each variable previously reviewed could be reevaluated in an effort to 
determine if practice changes have decrease the incidence of adverse respiratory 
events associated with residual NMB.   
Conclusion 
 The findings of this retrospective analysis may not have proven the 
hypothesis that Rocuronium is associated with increased risks of postoperative 
adverse respiratory events.  However, this capstone was instrumental in providing 
a statistically significant relationship between the usage of reversal agents and the 
incidence of adverse respiratory events. Residual neuromuscular blockade is not a 
new phenomenon.  It is hopeful that this capstone has provided the key 
stakeholders current evidence-based knowledge regarding the neuromuscular 
blocking agents Rocuronium and Vecuronium, the recommended practice of 
reversal, and the knowledge that TOF monitoring is now considered an AANA 
and ASA standard of care.   
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APPENDIX A 
FORREST GENERAL IRB APPROVAL LETTER 
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APPENDIX B 
UNIVERSITY OF SOUTHERN MISSISSIPPI IRB APPROVAL LETTER 
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APPENDIX C 
DATA COLLECTION TOOL 
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Legend 
Gender     M = male; F = female 
Age     Numerical number expressed in years 
ASA     I, II, III, IV 
Comorbidities R = respiratory; C = cardiac; N = neurological; 
H = hepatic; G = gastric; 
 R = renal; E = endocrine; O = other 
Inhalation agent S = Sevoflurane; D = Desflurane; I = Isoflurane 
Temperature Numerical number in Celsius 
BMI Numerical number 
Paralytic agent R = Rocuronium; V = Vecuronium 
Total dose of paralytic Numerical number expressed in milligrams 
Reversal Agent T = total; P = partial; N = no reversal used 
Time last dose of reversal Numerical number in minutes 
Time last dose/reversal to extubation Numerical number in minutes  
TOF Numerical number 
Type of procedure A = abdominal; E = extrathoracic; O = 
orthopedic; H = head; P = perinal; I = 
intrathoracic; N = neuroskeletal; S = spine; V = 
vascular 
Length of surgery Numerical number in minutes 
Narcotic F = fentanyl 
Narcotic dose Numerical number in micrograms 
Adverse event Y = yes; N = no 
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